ProCook Group (LON:PROC) Trading Up 5.9% – Should You Buy?
Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC
Procaps Group Secures $130 Million in Equity Investment and Completes Comprehensive Debt Restructuring, as New Investors Take Over Strategic Leadership
Corcept Therapeutics: New PROC SOC Treatment Option With Relacorilant Data Release
Procaps Group Receives Delisting Notice From Nasdaq
Procaps Group Receives Additional Delinquency Letter
Procaps Group Announces Key Shareholder and Board Decisions, Committee Restructuring, and Leadership Updates
Procaps Group Announces Financing, Shareholders Agreement and Board Updates
Procaps Receives Nasdaq Listing Determination; To Request Hearing and Further Stay Pending Hearing
Procaps Issues Shareholder Letter Update
Procaps Issues Shareholder Letter Update
Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024
Procaps Issues Shareholder Letter
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
Procaps Group Delays Filing of Annual Report on Form 20-F
Procaps Group Delays Filing of Annual Report on Form 20-F
Procaps Group – Notice to Shareholders
Procaps Group, S.A. (PROC) Q3 Earnings and Revenues Top Estimates
Procaps Group Reports Third Quarter 2023 Results
Statement from the Board of Directors of Procaps Group
Procaps Group and Genomma Lab Announce a Strategic Agreement to Manufacture and Market Softgel Products in Latin America
Procaps Group and Genomma Lab Announce a Strategic Agreement to Manufacture and Market Softgel Products in Latin America
Procaps Group Announces Appointment of Jose Antonio Vieira as Chief Executive Officer Starting 2024
Procaps Group Update on Third Quarter Results
Procaps Group to Report Third Quarter and Nine Months 2023 Results on Tuesday November 14, 2023
Procaps Group Wins First Place in Ranking of Innovative Companies in the Pharma Sector in Colombia
Procaps Group to Participate at CPHI Barcelona 2023
Procaps Group to Host Webinar on Colombian Pharma Market
Procaps Group to Participate at BTG 2023 LatAm CEO Conference and Roth 2023 Healthcare Opportunities Conference in October
Procaps Group Announces the Expansion of its Oncology Portfolio
Procaps Group S.A. (PROC) Q2 2023 Earnings Call Transcript
Procaps Group, S.A. (PROC) Q2 Earnings Surpass Estimates
Procaps Group Reports Second Quarter 2023 Results
Procaps Group to Report Second Quarter and First Half 2023 Results and Host Conference Call on Tuesday
Procaps Group Publishes White Paper on Innovative Gummy Technology
7 Penny Stocks Nearing Super Attractive Entry Points
Financial Results and Business Update Conference Call to be Held May 2023 in Conjunction with 20-F Filing
Procaps to Present at 2023 Annual J.P. Morgan Healthcare Conference
Procaps Group, S.A. (PROC) Q3 2022 Earnings Call Transcript
Procaps Group to Report Third Quarter and Nine Months of 2022 on November 14, 2022
Procaps Group Reports Fourth Quarter and Fiscal Year 2021 Financial Results
Procaps Group, S.A. (PROC) CEO Ruben Minski on Q3 2021 Results - Earnings Call Transcript
Procaps Group Reports Record Third Quarter 2021 Financial Results